Arbutus' ARB-1467 leads to HBsAg responses in Phase IIa for HBV infection

By Jaime De Leon | Dec 1, 2017 | 9:38 PM GMT

Arbutus Biopharma Corp. (NASDAQ:ABUS) reported data from 11 evaluable hepatitis B e antigen (HBeAg)-negative patients with chronic HBV infection in cohort 4 of the Phase IIa ARB-1467-002 trial showing that 0.4 mg/kg

Read the full 325 word article

How to gain access

Continue reading with a
two-week free trial.